

B16
But prevention of a disease associated with an activation of T-cells in a subject comprising administering a continuous disease associated, antigen activated T-cell line according to claim 40 to said subject.

[Please add the following new claims:]

56 (new). The method of claim 6 wherein each of the cytokines is used in a concentration of at least 10nM.

57 (new). The method of claim 1 where the T-cells are associated with a neoplastic disease.

B17 58 (new). The method of claim 17 wherein the disease is selected from the group consisting of chronic inflammatory bowel diseases, multiple sclerosis, type I diabetes, rheumatoid arthritis, psoriasis, atopic dermatitis, and asthma.

59 (new). The method of claim 25 in which the disease is asthma or atopic dermatitis.

REMARKS

The amendment is made to bring the claims into closer accord with U.S. practice.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
F:\H\hoib\Kaltoft 1\pto2ndpreamend.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 1, 6, 12, 14, 17, 19, 22, 24, 25, 29, 34, 37, 39, 40, 44 and 52 have been amended as follows:

1 (amended). A method of [expanding and selecting disease associated, antigen activated continuous T-cells] continuously culturing normal, human, disease associated, antigen activated T-cells comprising

(a) obtaining a tissue sample from a mammal [including a human being], the sample comprising disease associated, antigen activated T-cells and disease associated antigen or antigens, or

obtaining T-cells, comprising disease associated, antigen activated T-cells, and antigen-presenting cell from said mammal and mixing said cells with a disease associated antigen or antigens, and

(b) culturing said tissue sample or said mixture of cells and antigen(s) in the presence of at least two factors which promote T-cell growth and optionally one or more additional compounds,

where said mammal is a human being.

6 (amended). A method according to claim 1, wherein each of the cytokines is used in a concentration of at least 1 nM, preferably more than 2.5 nM[, more preferably more than 10 nM].

12 (amended). A method according to claim 1, wherein the disease is selected from the group consisting of [an] chronic inflammatory bowel disease[, such as Crohn's disease or ulcerative colitis], multiple sclerosis, type I diabetes, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer, cutaneous lymphoma, hepatic carcinoma, rejection-related disease, [or] and Graft-versus-host-related disease.

14 (amended). A method according to claim 13, wherein the compound enhances or inhibits the growth of a [certain] subgroup of T-cells[, such as] selected from the group consisting of inflammatory, regulatory or cytotoxic T-cells.

17 (amended). A method according to claim 1, wherein [disease

associated, antigen activated inflammatory T-cells are expanded and selected] the T-cells are inflammatory T-cells.

19 (amended). A method according to claim 18, wherein the inflammatory T-cells are cells contributing in a type 1 inflammatory [infiltrate] response producing IFN γ and TNF α .

22 (amended). A method according to claim 21, wherein the inflammatory T-cells are cells contributing in a type 2 inflammatory [infiltrate] response producing IL-4 or IL-5.

24 (amended). A method according to claim 17, wherein the disease is mediated or partially mediated by type 1 or type 2 inflammatory T-cells[, such as chronic inflammatory bowel diseases, for example Crohn's disease and ulcerative colitis, multiple sclerosis, type I diabetes, rheumatoid arthritis, psoriasis, atopic dermatitis, and asthma].

25 (amended). A method according to claim 1, wherein [disease associated, antigen activated regulatory T-cells are expanded and selected] the T-cells are regulatory T-cells.

29 (amended). A method according to claim 25, wherein the disease is mediated or partly mediated by type 2 inflammatory T-cells[such as asthma or atopic dermatitis].

34 (amended). A method according to claim 1, wherein [disease associated, antigen activated cytotoxic T-cells are expanded and selected] the T-cells are cytotoxic T-cells.

37 (amended). A method according to claim 34, wherein the one or more additional compounds is selected from GM-CSF, [caspase inhibitors such as Z-VAD] caspase inhibitors, Z-VAD, α -CD95, IL-10, IL-12, IL-16, and functionally similar compounds.

39 (amended). A method according to claim 34 wherein the disease is selected from the group consisting of malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer, hepatic carcinoma, [or] and cutaneous lymphoma.

40 (amended). A disease associated, antigen activated continuous T-cell line [obtainable] obtained by a method according to claim 1.

44 (amended). A vaccine comprising [activated disease associated, antigen activated inflammatory T-cells prepared

USSN - 09/720,371

according to the method of claim 1, or] a continuous, disease associated, antigen activated T-cell line according to claim 41.

52 (amended). A method for the treatment, alleviation or prevention of a disease associated with an activation of T-cells in a subject comprising administering a continuous disease associated, antigen activated T-cell line according to claim 40[, disease associated, antigen activated T-cells as produced according to any of claims 1-39, or a vaccine according to claims 44-48] to said subject.

Claims 56-59 have been added.